Skip to main content
  • Bookmarks
  • Register
  • Login

NIH OIR/OTT Logo

Main Menu

  • Partnerships

    Partnerships

    These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

    • Overview
    • Opportunities
    • Featured Technologies
    • Collaboration / CRADAs
    • Licensing Process
    • Forms / Model Agreements
    • Startups
    • Non-Profits
    • License Materials
    • Licensing FAQs
    • Business Opportunities
    • Product Showcase
    • Product Pipeline
    • Federal Register Notices

    The NIH cannot commercialize its discoveries even with its considerable size and resources — it relies instead upon partners. Typically, a royalty-bearing exclusive license agreement with the right to sublicense is given to a company from NIH to use patents, materials, or other assets to bring a therapeutic or vaccine product concept to market.

  • Royalties

    Royalties

    Information for inventors and licensees on the administration of royalties.

    • Information for NIH Inventors
    • Information for Licensees
    • License Notices / Reports
    • Royalty Coordinators
    • NIH Payment Center
    • CDC Payment Center

    Each year, hundreds of new inventions are made at NIH and CDC laboratories. Nine NIH Institutes or Centers (ICs) transfer NIH and CDC inventions through licenses to the private sector for further research and development and eventual commercialization.

  • Reports

    Reports

    These links provide access to reports tracking the success of NIH licensed products.

    • Annual Reports
    • Tech Transfer Statistics
    • Tech Transfer Metrics
    • Commercial Outcomes
    • HHS License-Based Vaccines & Therapeutics
    • Public Health & Economic Impact Study
    • Stories of Discovery
    • Chen Lecture Videos
    • NIH Patents and Active Patent Commercialization Licenses
    • Media Room
    • Tech Transfer Newsletters
    • NIH Patents and Patent Applications

    The NIH, CDC and FDA Intramural Research Programs are exceptionally innovative as exemplified by the many products currently on the market that benefit the public every day. Reports are generated from the commonly tracked metrics related to these products.

  • Resources

    Resources

    These links provide resources to those interested in the technology transfer activities at NIH.

    • Forms and Model Agreements
    • License Notices / Reports
    • Video Library
    • Inventor Resources
    • Presentations & Articles
    • FAQs
    • RSS Feeds
    • Inventor Showcase

    Past videos, lectures, presentations, and articles related to technology transfer at NIH are kept and made available to the public. These topics range from general technology transfer information to processes specific to NIH.

  • Policy & Regulations

    Policies & Regulations

    These links provide access to the policies and regulations surrounding partnering or collaborating with NIH.

    • Freedom of Information Act (FOIA)
    • PHS Technology Transfer Policy
    • Policies & Reports
    • Useful Links

    If a company would like to acquire rights to use or commercialize either an unpatented material, or a patented or patent-pending invention, a license is required. There are numerous policies and regulations surrounding the transfer or a technology from the NIH to a company or organization.

  • About

    About Us

    These links provide information about the Office of Technology Transfer.

    • Contact Us
    • Staff Directory
    • Management
    • FAQs
    • HHS Tech Transfer Offices & Contacts
    • Careers in Tech Transfer
    • Location & Directions
    • Feedback

    The NIH Office of Technology Transfer (OTT) plays a strategic role by supporting the patenting and licensing efforts of our NIH ICs. OTT protects, monitors, markets and manages the wide range of NIH discoveries, inventions, and other intellectual property as mandated by the Federal Technology Transfer Act and related legislation.

Breadcrumb

  1. Home
  2. Taxonomy
  3. Term
  4. NCI

siRNA SILENCING OF CSN5 GENE EXPRESSION

  • Read more about siRNA SILENCING OF CSN5 GENE EXPRESSION
US Application 61/045,251
Filed on 2008-04-15

Gene Expression Signature Of Genomic Instability In Breast Cancer

  • Read more about Gene Expression Signature Of Genomic Instability In Breast Cancer
US Application 61/097,101
Filed on 2008-09-15

METHODS OF TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS WITH DEL-1

  • Read more about METHODS OF TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS WITH DEL-1
US Application 61/094,285
Filed on 2008-09-04

USE OF MICRORNA-26 AS A PREDICTIVE MARKER FOR HEPATOCELLULAR CARCINOMA CLINICAL OUTCOME AND RESPONSE TO INTERFERON THERAPY

  • Read more about USE OF MICRORNA-26 AS A PREDICTIVE MARKER FOR HEPATOCELLULAR CARCINOMA CLINICAL OUTCOME AND RESPONSE TO INTERFERON THERAPY
US Application 61/131,800
Filed on 2008-06-11

Monoclonal Antibodies And Immunotoxins Reactive With Epidermal Growth Factor Receptor And Epidermal Growth Factor Receptor Variant III

  • Read more about Monoclonal Antibodies And Immunotoxins Reactive With Epidermal Growth Factor Receptor And Epidermal Growth Factor Receptor Variant III
US Application 61/044,190
Filed on 2008-04-11

N4 Modification Of Nucleotides For Increased Stability, Oral Boavailability, Targeted Delivery And Combination Therapy

  • Read more about N4 Modification Of Nucleotides For Increased Stability, Oral Boavailability, Targeted Delivery And Combination Therapy
US Application 60/943,172
Filed on 2007-06-11

IMMUNOTOXINS MADE WITH MODIFIED CHOLIX TOXIN AND USES THEREOF

  • Read more about IMMUNOTOXINS MADE WITH MODIFIED CHOLIX TOXIN AND USES THEREOF
US Application 61/058,872
Filed on 2008-06-04

Optimization Of Expression Of Multimeric Proteins

  • Read more about Optimization Of Expression Of Multimeric Proteins
US Application 61/052,916
Filed on 2008-05-13

OPTIMIZATION OF EXPRESSION OF HETERODIMERS

  • Read more about OPTIMIZATION OF EXPRESSION OF HETERODIMERS
US Application 61/052,239
Filed on 2008-05-11

Use Of Lasonolide A To Induce Premature Chromosome Condensation And As A Novel Anti-cancer Agent

  • Read more about Use Of Lasonolide A To Induce Premature Chromosome Condensation And As A Novel Anti-cancer Agent
US Application 61/137,193
Filed on 2008-07-28

Pagination

  • First page « First
  • Previous page ‹‹
  • …
  • Page 128
  • Page 129
  • Page 130
  • Page 131
  • Page 132
  • Page 133
  • Page 134
  • Page 135
  • Page 136
  • …
  • Next page ››
  • Last page Last »
Subscribe to NCI
NIH White Technology Transfer Logo

Return to Top

  • About
  • Privacy Notice
  • Accessibility
  • Web Policies & Notices
  • Open Data
  •  
  • For NIH Staff Only
  • HHS
  • NIH
  • HHS Vulnerability Disclosure
  • Connect
  • Twitter
  • LinkedIn
  • Contact
  • Feedback

Office of Technology Transfer, Office of Intramural Research, National Institutes of Health